Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1456 to 1470 of 2183 results for guidelines

  1. Ustekinumab for treating moderate to severe plaque psoriasis (TA180)

    Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.

    Technology appraisal guidance
    Last updated
    3 March 2017
    View recommendations

    Sections for TA180

  2. Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563)

    Evidence-based recommendations on abemaciclib (Verzenios) for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in adults who have not had endocrine-based therapy before.

    Technology appraisal guidance
    Published
    27 February 2019
    View recommendations

    Sections for TA563

  3. Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.

    Technology appraisal guidance
    Published
    13 May 2020
    View recommendations

    Sections for TA629

  4. Training and support for practitioners:- What is the effectiveness and cost effectiveness of different training programmes on the Mental Capacity Act 2005 at improving practice for practitioners involved in supporting decision-making, conducting capacity assessments and making best interests decisions?

    Any explanatory notes(if applicable) Why this is important:- The guideline committee agreed that effective training and support on the...

    Research recommendation
    Published
    19 December 2018

  5. AI technologies for detecting diabetic retinopathy (MIB265)

    NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .

    Medtech innovation briefing
    Published
    6 July 2021

  6. Maintaining the benefits of early intervention in psychosis services after discharge:- How can the benefits of early intervention in psychosis services be maintained once service users are discharged after 3 years?

    care or community mental health services these gains are diminished. The guideline recommends that trusts consider extending these...

    Research recommendation
    Published
    9 June 2015

  7. Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

    Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.

    Technology appraisal guidance
    Published
    8 May 2024
    View recommendations

    Sections for TA971

  8. Optilume for anterior urethral strictures (MIB241)

    NICE has developed a medtech innovation briefing (MIB) on Optilume for anterior urethral strictures .

    Medtech innovation briefing
    Published
    5 January 2021

  9. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)

    Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2-targeted therapy.

    Technology appraisal guidance
    Published
    10 June 2020
    View recommendations

    Sections for TA632

  10. Romosozumab for treating severe osteoporosis (TA791)

    Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.

    Technology appraisal guidance
    Published
    25 May 2022
    View recommendations

    Sections for TA791

  11. What is the efficacy and safety of COVID-specific antiviral drugs in combination with other COVID-specific antiviral drugs or COVID-specific neutralising monoclonal antibodies in people who do not need supplemental oxygen and are within 7 days of symptom onset?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    9 March 2022

  12. What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19?

    Source guidance details Comes from guidance COVID-19 rapid guideline: managing COVID-19 Number NG191 Date issued March

    Research recommendation
    Published
    9 March 2022

  13. What is the clinical and cost effectiveness of a combination management strategy consisting of sound therapy and tinnitus support?

    However, the recommendations on tinnitus support and management in this guideline specify that everyone should receive tinnitus support...

    Research recommendation
    Published
    17 March 2020

  14. What is the clinical and cost effectiveness of a combination management strategy consisting of sound therapy and tinnitus support?

    However, the recommendations on tinnitus support and management in this guideline specify that everyone should receive tinnitus support...

    Research recommendation
    Published
    17 March 2020

  15. Maternal request for caesarean birth: What support or psychological interventions would be appropriate for women who have a fear of vaginal childbirth and request a caesarean birth?

    would help to guide the optimal use of these limited resources and future guideline recommendations. Source guidance details Comes from...

    Research recommendation
    Published
    24 April 2023